article
Introducing NICE’s new board members
European Pharmaceutical Review explores who will be joining the National Institute of Health and Care Excellence (NICE)’s board as a new non-executive director on 1 April 2021.
List view / Grid view
UK National Institute for Health and Care Excellence (NICE)
Filter the results
news
New oral chronic lymphocytic leukaemia treatment made available on NHS
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
news
NICE approves gene therapy for spinal muscular atrophy
Zolgensma, a one-off, potentially curative treatment for type 1 spinal muscular atrophy, is set to become the most expensive drug ever approved for use on the UK’s NHS.
news
NICE recommends treatment for non-squamous, non-small cell lung cancer
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
news
NICE recommends Beovu (brolucizumab) for treatment of wet AMD
NICE has issued final guidance recommending Beovu (brolucizumab) to treat wet age-related macular degeneration in adults.
news
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
article
Cannabinoid series: medicinal cannabis and Brexit
Sarah Ellson from Fieldfisher spoke with European Pharmaceutical Review to discuss the position of medicinal cannabis in the UK and the impacts of Brexit.
news
NICE initiates new Innovative Licensing and Access Pathway for medicines
The new pathway developed by NICE for medicines to go from clinical trials to NHS patients is now in action.
news
British pharma responds to UK’s Chancellor’s new Spending Review
The ABPI has commented on the new Spending Review and outlined ways the UK government can help the life sciences sector.
news
Lilly’s Emgality (galcanezumab) recommended by NICE as migraine preventative
The UK's NICE has recommended Emgality (galcanezumab) for the prevention of migraine in adults with episodic and chronic migraine.
news
NICE recommends new chemo-free chronic lymphocytic leukaemia treatment
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
news
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
news
NICE to simplify how medicines are selected for evaluation
NICE has launched a public consultation for suggestions on updating how it selects the topics to develop guidance on, to improve medicine evaluations.
news
Tinostamustine granted Orphan Drug Designation by European Commission
Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).
news
Commonly used treatments for chronic pain do not work, says NICE
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.